August 14, 2025

Antidepressants May Benefit IBD Through Shared Mechanisms

Researchers examine how inflammatory bowel disease and depression share biological mechanisms and how treating one may improve outcomes in the other.

Conexiant

August 14, 2025

Are Immigration Raids Sending Patients Online?

Clinics and health plans are expanding telehealth services as increased immigration enforcement has coincided with some patients, including immigrant families, delaying or avoiding in-person medical visits.

KFF Health News

August 12, 2025

Advanced-Practice Providers Filling Rural ER Gaps

Rural emergency rooms across the U.S. are increasingly staffed by physician assistants and nurse practitioners instead of physicians, raising debates over care quality, staffing shortages, and access to emergency services.

KFF Health News

August 11, 2025

FDA Approves Ketamine Product for Surgical Pain Management

PharmaTher has received FDA approval for KETARx, a ketamine therapy for surgical pain management.

Conexiant

August 11, 2025

Nature-Based Programs May Help Mental Health, Evidence Uncertain

Adults diagnosed with anxiety, depression, or stress participated in structured nature-based interventions, which were associated with improvements in some mental health outcomes.

Conexiant

August 08, 2025

Mental Health Risk High in Patients with Hidradenitis Suppurativa

Hidradenitis suppurativa is associated with increased risks of depression and anxiety across all treatment levels, highlighting the importance of proactive psychiatric screening in dermatologic care.

Conexiant

August 07, 2025

Medical Oddities: Cocoa Fights the Flu?

Chocolate fights flu, snails regrow eyes, guts go neural, and past lives go clinical.

Conexiant

August 07, 2025

Flu Treatment Linked to Lower Neuropsychiatric Risk in Pediatric and Adolescent Patients

Subgroup analyses demonstrated a greater reduction in neurologic events than psychiatric events, though the reduction in psychiatric events was not statistically significant.

Conexiant

August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant